Market Overview

Asuragen Expands Oncology Portfolio with CE Marking and Launch of QuantideX® NGS DNA Hotspot 21 Kit

Share:

The panel accurately and sensitively detects over 1600 variants of
clinical significance

Asuragen,
Inc.
, a molecular diagnostics company delivering high-quality, easy
to use products for complex testing in genetics and oncology, today
announced the CE marking and launch of the QuantideX® NGS DNA
Hotspot 21 Kit*, a targeted, next-generation sequencing panel for the
detection of clinically relevant variants across a multitude of tumor
types, including non-small cell lung cancer, colorectal cancer, and
melanoma. By screening for the most commonly observed variants in a
simple workflow, the kit addresses existing laboratory and clinical
challenges surrounding NGS testing, including long time-to-result, high
assay complexity, and laborious data interpretation. The panel
represents an evolution of the company's existing QuantideX®
NGS Pan Cancer Kit, further streamlining the assay workflow and
harmonizing run conditions to enable parallel processing of samples with
the QuantideX® NGS RNA Lung Cancer Kit.

The QuantideX NGS DNA Hotspot 21 Kit features Asuragen's unique cGMP
manufactured, end-to-end NGS-in-a-Box™ design, providing the necessary
reagents to prepare sequencing-ready libraries in as little as a single
day, and incorporating push-button analytics to standardize results
after sequencing. Asuragen's proprietary Sample-Aware™
bioinformatics software assesses whether sufficient amplifiable DNA is
present, addressing common concerns of low quantity and quality samples.
Similar to the QuantideX NGS RNA Lung Cancer Kit, the assay is indicated
for use on the broadly installed Illumina MiSeq platform, further easing
laboratory implementation and adoption.

"The launch of the QuantideX NGS DNA Hotspot 21 Kit reinforces
Asuragen's commitment to provide simple, streamlined molecular testing
products for laboratories, even for complicated technologies like
next-generation sequencing," said Matthew McManus, MD, PhD, president
and CEO of Asuragen. "As with all our products, this kit reduces
laboratory complexity and optimizes both workflow and the quality of
results – all critical to providing the best care possible for patients."

*For Research Use Only in the US

For Research Use Only

About Asuragen

Asuragen is a molecular diagnostic company changing the way patients are
treated in genetics and oncology. The quality, simplicity and
sensitivity of its products brings precision medicine within reach.
Asuragen's diagnostic systems, composed of proprietary chemistry and
software, deliver powerful answers using broadly installed instrument
platforms. They are simple to adopt and expand the ability to serve
patients. Asuragen is a product foundry rapidly and efficiently
addressing current and emerging clinical needs, including cancer
diagnosis and monitoring, reproductive health and aging, serving
laboratories across a patient's lifespan with its best in class
diagnostic tests. For more information, visit www.asuragen.com.

View Comments and Join the Discussion!